Literature DB >> 1437141

Identification of complex formation between two intracellular tyrosine kinase substrates: human c-Rel and the p105 precursor of p50 NF-kappa B.

M Neumann1, K Tsapos, J A Scheppler, J Ross, B R Franza.   

Abstract

Immune complexes of the product of the c-rel protooncogene and of p105, the p50 NF-kappa B precursor, isolated from human T-lymphoblastoid cell lines are comprised of multiple proteins. Only p105 and human c-Rel (hc-Rel) are common to complexes precipitated with antiserum directed against either p105 or hc-Rel. Both proteins are inducible by phytohemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA) and their subcellular distribution is affected by this induction. We demonstrate that the Rel immune complex contains a protein with a molecular weight in the 40 kDa range (p40) which apparently is exclusively cytoplasmic. We were not able to detect p40 in the p105 immune complex, though hc-Rel is present. This indicates that hc-Rel exists in different multi-protein complexes and fits a model of functional regulation mediated by differential protein-protein interaction. We also demonstrate considerable isoform diversity of both hc-Rel and p105. We show that this heterogeneity is, in part, the result of phosphorylation. Furthermore, we demonstrate that p105 and hc-Rel are tyrosine kinase substrates. This finding indicates a role for both proteins in intracellular signal transduction pathways which are modulated by modification of their phosphorylation status.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437141

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  c-Rel plays a key role in deficient activation of B cells from a non-X-linked hyper-IgM patient.

Authors:  Kristina T Lu; Frank L Sinquett; Rebecca L Dryer; Charles Song; Lori R Covey
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

2.  The c-Rel Transcription Factor in Development and Disease.

Authors:  Thomas D Gilmore; Steve Gerondakis
Journal:  Genes Cancer       Date:  2011-07

3.  Transformation of avian fibroblasts overexpressing the c-rel proto-oncogene and a variant of c-rel lacking 40 C-terminal amino acids.

Authors:  J Kralova; J D Schatzle; W Bargmann; H R Bose
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

4.  The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.

Authors:  R Hrdlicková; J Nehyba; A Roy; E H Humphries; H R Bose
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

5.  Alternate RNA splicing of murine nfkb1 generates a nuclear isoform of the p50 precursor NF-kappa B1 that can function as a transactivator of NF-kappa B-regulated transcription.

Authors:  R J Grumont; J Fecondo; S Gerondakis
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

6.  Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells.

Authors:  R G Bryan; Y Li; J H Lai; M Van; N R Rice; R R Rich; T H Tan
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Evidence for the involvement of a nuclear NF-kappa B inhibitor in global down-regulation of the major histocompatibility complex class I enhancer in adenovirus type 12-transformed cells.

Authors:  X Liu; R Ge; R P Ricciardi
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

8.  Proteolytic degradation of MAD3 (I kappa B alpha) and enhanced processing of the NF-kappa B precursor p105 are obligatory steps in the activation of NF-kappa B.

Authors:  K H Mellits; R T Hay; S Goodbourn
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

9.  Diverse molecular mechanisms of inhibition of NF-kappa B/DNA binding complexes by I kappa B proteins.

Authors:  T Léveillard; I M Verma
Journal:  Gene Expr       Date:  1993

10.  NF-kappa B/Rel family members are physically associated phosphoproteins.

Authors:  C C Li; M Korner; D K Ferris; E Chen; R M Dai; D L Longo
Journal:  Biochem J       Date:  1994-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.